Emergency Use Authorization of a new drug for the treatment of COVID19

“A new drug for the treatment of COVID19 has got Emergency Use Authorization (EUA) by DCGI”

DCGI has given permission for the emergency use of the drug 2-deoxy-D-glucose (2-DG) for the treatment of COVID19. This drug is to be used only for hospitalized mild to moderate COVID19 patients. The drug is developed by collaboration of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defense Research and Development Organization (DRDO) and Dr. Reddy’s Laboratories. The drug comes in sachet form, to be dissolved in water and taken orally. The drug acts by mixing up with virus infected cells and thereby preventing virus growth by stopping viral synthesis and energy production. 

“It’s a selective accumulation in virally infected cells that make this drug unique. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients,” INMAS-DRDO said. 

According to INMAS-DRDO, results of clinical trial shows that this drug helps in faster recovery of hospitalized patients and reduces dependence on oxygen. This drug is expected to save valuable lives due to its mechanism of action (MOA). As it reduces the hospital stay, it will also help to lessen the load on health infrastructure.

As it is a generic drug and is easily available in our country hence, can be produced easily. The research was started in the first wave of pandemic last year April. Phase II trials were conducted on 110 patients in 17 hospitals. Results have shown a faster recovery and 2-3 days difference in normalizing the vital parameters. Clinical trial phase III results have shown improved conditions of patients significantly and reduced dependence on oxygen.

Tags : #Spotlight #EUA #2-DG #COVID19 #Drugforcovid #Medicircle #SmitaKumar #DCGI

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024